顺铂与奈达铂同期放化疗治疗局部晚期鼻咽癌的疗效对比  

Efficacy of cisplatin versus nedaplatin concurrent chemotherapy for locally advanced nasopharyngeal carcinoma

作　　者：邱杨[1] 周振萍[1] 钟晓鸣[1] 

机构地区：[1]江西省肿瘤医院放疗科,南昌330029

出　　处：《中国肿瘤临床与康复》2017年第12期1466-1468,共3页Chinese Journal of Clinical Oncology and Rehabilitation

摘　　要：目的探讨顺铂与奈达铂同期放化疗治疗局部晚期鼻咽癌的疗效对比。方法选取2011年1月至2013年12月间江西省肿瘤医院收治的312例局部晚期鼻咽癌患者,根据化疗方案不同分为顺铂组178例和奈达铂组134例。两组患者均采用同期放化疗治疗,顺铂组患者给予顺铂化疗,奈达铂组患者给予奈达铂化疗,对比两组患者近期疗效、2年生存率、2年复发率及不良反应。结果顺铂组患者总有效率为94.4%(168/178),2年生存率为85.4%(152/178),无进展生存率为82.0%(146/178),复发率为12.4%(22/178),转移率为16.3%(29/178);奈达铂组患者总有效率为94.0%(126/134),2年生存率为86.6%(116/134),无进展生存率为82.8%(111/134),复发率为12.7%(17/134),转移率为16.4%(22/134)。两组患者总有效率、2年生存率及复发转移率比较,差异无统计学意义(P>0.05);两组患者不良反应症状基本相同,但奈达铂组患者胃肠道和口腔黏膜反应均明显低于顺铂组,差异均有统计学意义(均P<0.05)。结论顺铂与奈达铂在局部晚期鼻咽癌患者同期放化疗治疗中,近期疗效相近,但奈达铂能有效减轻不良反应,值得临床推广。Objective To compare the efficacy of concurrent chemotherapy of cisplatin and nedaplatin in the treatment of locally advanced nasopharyngeal carcinoma. Methods A total of 312 patients with locally advanced nasopharyngeal carcinoma admitted to Jiangxi Tumor Hospital from January 2011 to December 2013. According to the chemotherapy regimens,patients were divided into cisplatin group（ 178 patients） and nedaplatin group（ 134 patients）. The patients in both groups were treated with concurrent chemotherapy. All the patients were treated with concurrent chemotherapy. Patients in the cisplatin group were given cisplatin and patients in the nedaplatin group were given nedaplatin. The short-term efficacy,2-year survival rate,2-year recurrence rate and side effects were compared between the two groups. Results The overall response rate was 94. 4%（ 168/178）,2-year survival rate was 85. 4%（ 152/178）,progression-free survival rate was 82. 0%（ 146/178）,recurrence rate was 12. 4%（ 22/178） and metastases rate was 16. 3%（ 29/178） for the cisplatin group. The overall response rate was 94. 0%（ 126/134）,2-year survival rate was 86. 6%（ 116/134）,progression-free survival rate was 82. 8%（ 111/134）,recurrence rate was 12. 7%（ 17/134） and metastases rate was 16. 4%（ 22/134）. There was no significant difference in overall response rate,2-year survival rate and metastases rate（ all P〈0. 05）. Conclusion The shortterm efficacy of cisplatin and nedaplatin in the treatment of locally advanced nasopharyngeal carcinoma is similar and nedaplatin can effectively relieve the adverse reactions,which is worthy to be popularized and applied clinically.

关 键 词：鼻咽肿瘤 同期放化疗 顺铂 奈达铂 

分 类 号：R739.63[医药卫生—肿瘤]